Eficacia de un nuevo alquilfosfolípido frente a la leishmaniosis canina experimental por Leishmania infantum
- Olias Molero, Ana Isabel
- José María Alunda Rodríguez Doktorvater
Universität der Verteidigung: Universidad Complutense de Madrid
Fecha de defensa: 27 von Januar von 2021
- José María Aguado García Präsident
- Juan José Torrado Durán Sekretär
- Juan Antonio Castillo Hernández Vocal
- Antonio Osuna Carrillo de Albornoz Vocal
- Jorge Antonio Guisantes del Barco Vocal
Art: Dissertation
Zusammenfassung
Leishmaniasis is a widely distributed vectorial disease caused by species of the genus Leishmania. Disease outcome depends on the Leishmania species involved and the functionality of the host’s immune response. Visceral leishmaniasis, produced L. donovani and L. infantum, is the most severe condition. Dogs can be infected by a variety of Leishmania species and they are considered the main reservoir for human infections by L.infantum (zoonotic visceral leishmaniasis, ZVL). Canine leishmaniasis (CanL) is prevalent and a first order veterinary pathology in endemic areas. No human vaccine is available and the currently marketed veterinary vaccines have limitations, environmental control is unfeasible and efficacy of dog culling has been challenged. Therefore, the control of CanL – and ZVL – relies on the use of repellents and, mainly, the treatment of infected dogs. However, the available therapeutic arsenal includes the same compounds used against human leishmaniasis and all of them have serious drawbacks considering efficacy, toxicity and resistance phenomena...